Chemotherapy-Induced Nausea and Vomiting (CINV)

APF530 (Granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. Future Oncology. Schnadig D et al.

A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation. Cancer Management and Research. Mason JW et al.

Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron. Journal of Experimental Pharmacology. Ottoboni TB et al.

Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Supportive Care in Cancer. Raftopoulos H et al.

Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy. The Journal of Community and Supportive Oncology. Boccia R et al.

Pain Management

Essentials of Local Anesthetic Pharmacology. Anesthesia Progress. Becker D et al.

Biochronomer® Technology

Biochronomer™ technology. Expert Opinion on Drug Delivery. Heller J et al.

Poly(ortho esters)-From Concept to Reality. BioMacromolecules. Heller J et al.

Poly(ortho esters): synthesis, characterization, properties and uses. Advanced Drug Delivery Reviews. Heller J et al.